
The most common adverse reactions (≥20%) with Tucatinib in combination with trastuzumab and capecitabine in patients with metastatic breast cancer are diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash.
The most common adverse reactions (≥20%) with Tucatinib in combination with trastuzumab in patients with unresectable or metastatic colorectal cancer are diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia.
from FDA,2023.01
Common side effects of Tucatinib and management suggestionsLike other medications, Tucatinib may cause side effects, but not everyone will experience them. Very common side effects···【more】
Article source:Lucius LaosRelease date:2026-05-26Recommended:84
Common Side Effects of Tucatinib and Their ManagementIn clinical studies, nearly all patients experienced some side effects, but most were mild to moderate. When tucatinib is combi···【more】
Article source:Lucius LaosRelease date:2026-05-25Recommended:92

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643